Novavax's protein-based COVID-19 vaccine campaigner demonstrated astir 90% efficacy against COVID-19, successful a cohort wherever fractional the cases were owed to the caller U.K. variant, the institution said in a property release connected Thursday.
However, the quality was little affirmative from a proceedings successful South Africa, wherever wide vaccine efficacy was nether 50% against cases mostly owed to the trickier South African variant.
Moreover, findings from that survey suggested anterior corruption with the wild-type strain whitethorn not afloat support against caller corruption from the variant strain.
The vaccine is simply a recombinant mentation of the coronavirus spike protein, produced successful insect cells, and frankincense represents a comparatively accepted exertion that besides differs from the COVID-19 vaccines present successful distribution.
In an interim investigation of a signifier III proceedings conducted successful Great Britain, 89.3% efficacy (95% CI 75.2%-95.4%) was achieved against PCR-confirmed symptomatic COVID-19. This was based connected 62 COVID-19 cases among immoderate 15,000 participants, with 56 observed successful the placebo radical and six successful those receiving the progressive vaccine. Of these 62 cases, lone 1 was classified arsenic severe.
And Novavax touted a preliminary investigation indicating that 32 of the 62 cases were the alleged U.K. coronavirus variant. Based connected PCR testing, vaccine efficacy was 95.6% against the archetypal COVID-19 strain and 85.6% against the U.K. variant strain successful the post-hoc analysis.
The signifier III survey enrolled adults ages 18-84, including 27% property 65 and older. The superior endpoint was PCR-confirmed symptomatic COVID-19 astatine slightest 7 days aft the 2nd of the two-dose regimen successful serologically antagonistic participants.
Preliminary information information indicated that adverse events were infrequent and mostly comparable betwixt groups. The shaper said it plans to stock afloat results of the proceedings via pre-publication servers and taxable them to a peer-reviewed journal.
South African Variant More Elusive
Novavax besides provided topline results from a signifier IIb proceedings successful South Africa of the vaccine successful which astir 6% of participants were HIV-positive. Here, the vaccine showed 60% efficacy (95% CI 19.9%-80.1%) successful the HIV-negative population; it was overmuch little effectual successful the HIV-infected participants, starring to wide vaccine efficacy of 49.4% (95% CI 6.1%-72.8%) for the full survey population.
There were 29 COVID-19 cases successful the placebo radical (one severe) and 15 successful the vaccine radical (none severe).
Most of these cases progressive the alleged South African variant that includes aggregate mutations successful the coronavirus spike protein. Preliminary sequencing information indicated that the variant was liable for 25 of 27 cases analyzed.
The proceedings enrolled implicit 4,400 patients starting successful August, with information from September done mid-January. However, astir a 3rd of patients enrolled were seropositive for COVID-19 corruption astatine baseline. Based connected erstwhile the proceedings started, pre-trial infections were thought to beryllium caused by the archetypal non-variant strain, portion infections occurring during the proceedings were variant virus.
"These information suggest that anterior corruption with COVID-19 whitethorn not wholly support against consequent corruption by the South Africa flight variant," the shaper said.
The merchandise noted that plans are underway to make a booster dose and/or operation bivalent vaccine for the caller strains, and to trial these caller vaccines successful the 2nd 4th of 2021.
Novavax uses nanoparticle exertion and a proprietary adjuvant with the recombinant protein. The vaccine tin beryllium stored astatine 2º to 8º C and shipped successful a ready-to-use liquid formulation.
Last Updated January 29, 2021